A Prospective, Single Center, Post-Market Observational Study to Assess the Efficacy, Safety, and Patient Reported Outcomes of Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

CeQur Corporation1 site in 1 country8 target enrollmentJune 2014

ConditionsType 2 Diabetes Mellitus

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Type 2 Diabetes Mellitus
Sponsor: CeQur Corporation
Enrollment: 8
Locations: 1
Primary Endpoint: Change in glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood) from baseline at Week 12
Status: Terminated
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).

Detailed Description

This is a prospective, single center, post-market observational study to assess the efficacy, safety, and patient reported outcomes of insulin delivery with PaQ® in patients with type 2 diabetes mellitus (T2DM) who are currently receiving basal/bolus insulin therapy with or without oral anti-diabetic drugs (OADs) for glycemic control. The patient's participation in the study is comprised of three phases: screening/baseline evaluation, transition to PaQ use and optimization, and PaQ treatment period. The use of these phases will allow an orderly transition to PaQ treatment as well as a reliable construct from which to interpret the final data.

Registry

clinicaltrials.gov

Start Date

June 2014

End Date

November 2014

Last Updated

9 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

CeQur Corporation

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Is at least 18 years of age
•Has a clinical diagnosis of T2DM, as determined by clinical history and medication usage
•Has an A1C ≥ 7.0% and ≤ 11.0%;
•Is treated with basal-bolus insulin therapy (at least 2 injections per day) with or without OADs, and/or glucagon-like peptide-1 (GLP-1) agonist for at least 3 months and has not had a change (addition or discontinuation of existing drug or change in dose) in their OADs for the last 8 weeks
•Determined by the investigator that insulin requirements to achieve glycemic targets can be met by the insulin capacity of the PaQ device
•If on concomitant metformin, has serum creatinine \<1.5 mg/dL (male) or \<1.4 mg/dL (female)
•If female, and of child-bearing potential, has a negative urine pregnancy test at screening and must be using adequate means of contraception as determined by the Investigator
•Is clinically euthyroid as judged by the Investigator
•Is able to understand and sign the required study documents and comply with the clinical investigational plan (CIP) requirements
•Is deemed capable by the Investigator to perform the requirements of the CIP, including use of PaQ, frequent self-monitoring of blood glucose

Exclusion Criteria

•Is poorly compliant with the currently prescribed diabetes regimen, as determined by the Investigator
•Is poorly compliant with prescribed self-monitoring of blood glucose, as determined by the Investigator
•Is currently taking or has taken sulfonylureas within the last 2 months
•Has a BMI greater than 40 kg/m2
•Has experienced recurrent severe hypoglycemia (\> 2 episodes) requiring assistance during the past 6 months
•Has existing dermal irritation/inflammation over the abdominal area that may interfere with use of PaQ, as determined by the Investigator
•Has known clinically significant hypersensitivity to skin adhesives
•Is female and if of child-bearing potential, is pregnant, lactating, or planning to become pregnant
•Is currently being treated with or expected to require or undergo treatment with systemic steroids by oral, intravenous, or intramuscular route (inhaled with low systemic exposure is permitted)
•Currently abuses drugs or alcohol or has a history of abuse that in the Investigator's opinion would cause the individual to be non-compliant

Outcomes

Primary Outcomes

Change in glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood) from baseline at Week 12

Time Frame: 12 weeks

Secondary Outcomes

Change in A1C from baseline at Week 8(8 weeks)
Change in 7-point blood glucose profiles and 1.5-2 hour postprandial blood glucose excursions (average and by meal) from baseline at week 12(12 weeks)
Change in insulin dose (total, basal, and bolus) from Baseline at week 12(12 weeks)
Change in body weight from baseline at Week 12(12 weeks)
Occurrence of hypoglycemia, adverse events, and/or dermal irritation at PaQ application site(Throughout the study)
Change in fasting plasma glucose from baseline at end of study week 12(12 weeks)
Change in measures of PROs from baseline at Week 12(12 weeks)